The tourette syndrome (TS) treatment market is expected to register a CAGR of 10.4% over the forecast period.
The outbreak of the COVID-19 pandemic led to worsening symptoms, including tics, hyperactivity, rage attacks, obsessions/compulsions, and anxiety amongst virus-affected people, which increased demand for Tourette syndrome treatment drugs. For instance, according to the research study published by the eClinicalMedicine Journal in February 2023, the incidence of tics in young people and children surged across all age and sex groups during the initial phase of the pandemic. As per the same source, the incidence of mental health disorders such as anxiety also increased amongst those suffering from tic symptoms. Hence, the rising incidence of tics symptoms during the initial phase of the pandemic led to an increased demand for medications, therapies, and other treatments for Tourette syndrome. However, with the decrease in COVID-19 cases worldwide, the incidence of tics is also controlled, and the market is expected to register stable growth during the forecast period.
The major factors driving the growth of the market are the increasing cases of Tourette syndrome across the globe and the rising focus on Tourette syndrome research. In addition, increasing research work and studies on Tourette syndrome to investigate underlying causes and treatment efficacy across the globe are also anticipated to propel market growth. For instance, according to the data released by ClinicalTrials.gov in March 2023, Tourette syndrome (TS) and chronic tic disorder (CTD) affect approximately 1% of 5-18-year-olds globally. In addition, according to the data released by the ADHD Foundation in March 2022, globally, approximately 1 out of 100 school-aged children have diagnosable TS. As per the same source, more than 300,000 children and adults are living with TS in the United Kingdom. Furthermore, around 85% of people with TS suffer from various neurological diseases such as Attention Deficit Hyperactivity Disorder (ADHD), Obsessive Compulsive Disorder (OCD), and Anxiety. Moreover, the rising number of clinical trials related to TS is also projected to drive market growth during the forecast period. For instance, in November 2022, Emalex Biosciences closed a Series D funding of around USD 250 million for its phase III trial of ecopipam drug for Tourette syndrome.
Therefore, the high prevalence of TS all over the world and the rising number of clinical trials are projected to drive market growth during the forecast period. However, a lack of awareness about Tourette syndrome in developing regions is likely to impede the market's growth over the forecast period.
The increasing use of antipsychotic drugs and their efficacy in treating Tourette syndrome is one of the major factors driving the segment's growth over the forecast period. For instance, per the study published by Cureus Journal in February 2022, antipsychotic drugs have been commonly used as a treatment for Tourette syndrome since Food and Drug Administration approval. Haloperidol and pimozide have been used for a long time and have shown significant efficacy. Haloperidol can cause a 91.0% reduction in the severity of tics when given at the maximum dose. Therefore, such instances indicating the high effectiveness of antipsychotic drugs towards treating the Tourette syndrome segment are projected to drive segment growth over the forecast period. Furthermore, the rising number of clinical trials testing the efficacy of antipsychotic drugs for treating TS disease is also projected to drive segment growth during the forecast period. For instance, in March 2023, Emalex Biosciences announced that the first patient was dosed in its Phase 3 clinical trial evaluating ecopipam for treating Tourette Syndrome.
Therefore, the high efficacy of antipsychotic drugs in treating TS and the rising number of clinical trials is projected to drive segment growth during the forecast period.
Key product launches, high concentration of market players or manufacturer's presence, acquisitions and partnerships among major players, and public and private initiatives toward Tourette syndrome in the United States are some of the factors driving the growth of the Tourette syndrome treatment market in the country. For instance, the Tourette Association of America celebrates Tourette Syndrome Awareness Month from May 15 to June 15 every year to increase awareness about the syndrome among people. Thus, such instances are anticipated to drive the market growth in the country.
Therefore, owing to the aforementioned factors, the studied market's growth is anticipated to grow in the North American region.
This product will be delivered within 2 business days.
The outbreak of the COVID-19 pandemic led to worsening symptoms, including tics, hyperactivity, rage attacks, obsessions/compulsions, and anxiety amongst virus-affected people, which increased demand for Tourette syndrome treatment drugs. For instance, according to the research study published by the eClinicalMedicine Journal in February 2023, the incidence of tics in young people and children surged across all age and sex groups during the initial phase of the pandemic. As per the same source, the incidence of mental health disorders such as anxiety also increased amongst those suffering from tic symptoms. Hence, the rising incidence of tics symptoms during the initial phase of the pandemic led to an increased demand for medications, therapies, and other treatments for Tourette syndrome. However, with the decrease in COVID-19 cases worldwide, the incidence of tics is also controlled, and the market is expected to register stable growth during the forecast period.
The major factors driving the growth of the market are the increasing cases of Tourette syndrome across the globe and the rising focus on Tourette syndrome research. In addition, increasing research work and studies on Tourette syndrome to investigate underlying causes and treatment efficacy across the globe are also anticipated to propel market growth. For instance, according to the data released by ClinicalTrials.gov in March 2023, Tourette syndrome (TS) and chronic tic disorder (CTD) affect approximately 1% of 5-18-year-olds globally. In addition, according to the data released by the ADHD Foundation in March 2022, globally, approximately 1 out of 100 school-aged children have diagnosable TS. As per the same source, more than 300,000 children and adults are living with TS in the United Kingdom. Furthermore, around 85% of people with TS suffer from various neurological diseases such as Attention Deficit Hyperactivity Disorder (ADHD), Obsessive Compulsive Disorder (OCD), and Anxiety. Moreover, the rising number of clinical trials related to TS is also projected to drive market growth during the forecast period. For instance, in November 2022, Emalex Biosciences closed a Series D funding of around USD 250 million for its phase III trial of ecopipam drug for Tourette syndrome.
Therefore, the high prevalence of TS all over the world and the rising number of clinical trials are projected to drive market growth during the forecast period. However, a lack of awareness about Tourette syndrome in developing regions is likely to impede the market's growth over the forecast period.
Tourette Syndrome Treatment Market Trends
Antipsychotics Segment is Expected to Witness Significant Growth Over the Forecast Period
Antipsychotic drugs are expected to hold a significant market share due to their ability to treat tics to a greater extent than non-antipsychotic drugs. Antipsychotic drugs were developed for treating schizophrenia, hence the term antipsychotic. These medications work by blocking another chemical in the brain called dopamine, specifically by blocking dopamine receptors, mainly the D2 receptor. Thus, such a robust therapeutic effect of antipsychotics is one of the significant factors driving the segment's growth over the forecast period.The increasing use of antipsychotic drugs and their efficacy in treating Tourette syndrome is one of the major factors driving the segment's growth over the forecast period. For instance, per the study published by Cureus Journal in February 2022, antipsychotic drugs have been commonly used as a treatment for Tourette syndrome since Food and Drug Administration approval. Haloperidol and pimozide have been used for a long time and have shown significant efficacy. Haloperidol can cause a 91.0% reduction in the severity of tics when given at the maximum dose. Therefore, such instances indicating the high effectiveness of antipsychotic drugs towards treating the Tourette syndrome segment are projected to drive segment growth over the forecast period. Furthermore, the rising number of clinical trials testing the efficacy of antipsychotic drugs for treating TS disease is also projected to drive segment growth during the forecast period. For instance, in March 2023, Emalex Biosciences announced that the first patient was dosed in its Phase 3 clinical trial evaluating ecopipam for treating Tourette Syndrome.
Therefore, the high efficacy of antipsychotic drugs in treating TS and the rising number of clinical trials is projected to drive segment growth during the forecast period.
North America is Expected to Register Significant Share in the Tourette Syndrome Treatment Market Over the Forecast Period
North America is expected to register a significant share in the overall Tourette syndrome treatment market over the forecast period. The growth is due to factors such as the increasing prevalence of Tourette syndrome and increasing research related to the syndrome in this region. For instance, as per the report published by Tourette Canada in January 2022, Tourette syndrome affects approximately 1.0% of the population. However, some recent studies suggest that the prevalence rate may be as high as 3.8%. Tics are quite common in childhood, with studies showing that 24.0% of children may develop simple tics. Therefore, such instances indicate that the demand for Tourette syndrome treatment may increase, propelling the market growth for treatments. Furthermore, according to the article published by Medical News Today in November 2021, approximately 1 in every 160 children in the United States currently suffers from Tourette syndrome.Key product launches, high concentration of market players or manufacturer's presence, acquisitions and partnerships among major players, and public and private initiatives toward Tourette syndrome in the United States are some of the factors driving the growth of the Tourette syndrome treatment market in the country. For instance, the Tourette Association of America celebrates Tourette Syndrome Awareness Month from May 15 to June 15 every year to increase awareness about the syndrome among people. Thus, such instances are anticipated to drive the market growth in the country.
Therefore, owing to the aforementioned factors, the studied market's growth is anticipated to grow in the North American region.
Tourette Syndrome Treatment Industry Overview
The tourette syndrome treatment market is consolidated and competitive, with most of the players competing to increase market share. Rising competition, rapid technological advancements, and a focus on research are key factors that strongly impact the market. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known, including AstraZeneca Plc, Viatris Inc. (Mylan Inc.), Otsuka Holdings Co. Ltd., Reviva Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd. (Auspex Pharmaceuticals, Inc.), among others.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD)
6 COMPETITIVE LANDSCAPE
Methodology
LOADING...
